BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies [4] - The company awarded an inducement grant to a new employee as part of its 2025 Inducement Plan [1] Summary by Sections Inducement Grant - An inducement grant was awarded on January 10, 2026, to an individual hired in December 2025 [1] - The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock at an exercise price of $13.19 per share, which is the closing price on the grant date [2] - The stock options will vest 1/4 on the first anniversary of the employee's start date and in 36 equal monthly installments thereafter, contingent on continued service [2] Plan Details - The awards were granted outside of BBOT's stockholder-approved equity incentive plans and are part of the 2025 Inducement Plan adopted in October 2025 [3] - The compensation committee, composed solely of independent directors, approved the awards as a material inducement for the new employee [3] Company Overview - BBOT is advancing a pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, aiming to improve outcomes for patients with cancers driven by prevalent oncogenes [4]